Kashish Goel

Director, Transcatheter Heart Valve Interventions, Vanderbilt @VUMC_heart. Associate Professor of Medicine; Opinions are my own and not the views of my employer

[Kashish Goel @kashishgoelmd]

@rajdhruv10 Hi Dhruv, please send an email to
Charlene and she can send you the application

[Kashish Goel @kashishgoelmd]

2027 Structural Heart Fellowship | Vanderbilt University Medical Center

We currently have an opening in our Structural Interventional Cardiology Fellowship for a position beginning in July 2027. Interviews in late September

A unique opportunity to train at the forefront of structural heart intervention, with exposure to the full spectrum of transcatheter therapies, complex structural procedures, and innovative clinical trials.

Interested? Please reach out to me directly or contact Charlene M. Thompson at [email protected].

[Kashish Goel @kashishgoelmd]

@djc795 @jtsaxon @duanepinto @GreggWStone Graphs look exactly the same! Thanks for sharing..

[Kashish Goel @kashishgoelmd]

@djc795 @jtsaxon So, the only way is to prevent crossovers early?

[Kashish Goel @kashishgoelmd]

Another interesting data point that would be helpful: How the investigators chose to intervene at the time of crossover as >50% didn’t get intervention? Was there a change in their TEER eligibility?

Data from Clasp II TR becomes even more important as crossovers were not allowed until 1 year I think

[Kashish Goel @kashishgoelmd]

@jtsaxon They were crossed over after the first event, HFH. Are you saying they were admitted to cross over?

[Kashish Goel @kashishgoelmd]

@djc795 @TagliariPaula Creates a lot of hype for CLASP II TR being presented at TCT 2026!

[Kashish Goel @kashishgoelmd]

@djc795 @TagliariPaula Still trying to digest the data. How do we explain only 7 point KCCQ difference at 1 year but HFH benefit?

Also, in the supplement, table S6 shows that 117 pts had 3+ TR, 94 had 4+ and 26 had 5+. Does this trial imply that treating 3+ TR in symptomatic HF has a benefit?

[Kashish Goel @kashishgoelmd]

@djc795 Impressive line-up! Looking forward to TCT 2026

[Kashish Goel @kashishgoelmd]

We started the SAPIEN M3™ Transseptal TMVR Program at Vanderbilt University Medical Center a couple of months ago, bringing an innovative, minimally invasive option to patients with complex mitral valve disease.

I’m grateful that our first patient graciously agreed to share her story through Vanderbilt Health News. Her trust means so much to our entire team.

This program, together with three additional transseptal TMVR clinical trials currently ongoing at VUMC, with more new trials coming soon, allows us to offer transseptal TMVR options to a very broad range of patients with mitral valve disease.

Together, these efforts position Vanderbilt among the leading transcatheter mitral valve centers in the U.S. and potentially the world.

The future of transcatheter mitral valve replacement is here — at VUMC.

@colinbarkerMD @VUMCDiscoveries @VUMChealth

https://t.co/ZFl8QFnPyI

[Kashish Goel @kashishgoelmd]

@djc795 @jtsaxon @JACCJournals @HamidNadira @Columbia @MayoClinic @PierreEliasMD @crfheart Incredible study!! Looking forward to the AI-ECG and how it can help diagnose valvular heart disease early

[Kashish Goel @kashishgoelmd]

Presenting our age-stratified analysis from the EARLY TAVR trial showing that age did not affect impact of early intervention in asymptomatic severe AS!

[CircInterventions @CircIntv]

Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR trial. Early TAVR versus clinical survelliance consistent among all age groups above 65 years @kashishgoelmd @PhilGenereuxMD https://t.co/3SGDxiXhcF

[Pradeep Yadav @PradeepYadavMD]

Very important for valve ICs to join+participate in this ! Appreciate @SCAI efforts. Wish @ACCinTouch would do the same @PaulMahoneyMD @PaulTeirstein @kashishgoelmd @sameergafoor @AGoldsweig @SachinGoelMD @SuzanneJBaron

[Kashish Goel @kashishgoelmd]

@aelsab Great!! Congratulations

[Pradeep Yadav @PradeepYadavMD]

Should professional societies like @SCAI get opinion from its members on critical matters? Yes- as it represents it members and decisions affect them. No - a small indoor committee knows the best! Please retweet to get some reasonable responses @ACCinTouch @kashishgoelmd @KHERA_MD @SVRaoMD @djc795 @SachinGoelMD @PaulMahoneyMD

[Kashish Goel @kashishgoelmd]

Our first J-Valve case as part of the JOURNEY Trial for native aortic regurgitation is officially in the books. This represents an important step forward in expanding transcatheter options for AR for our region and beyond.

Just as important as the technology is the team behind it. From advanced imaging to anesthesia to intervention, this was a true multidisciplinary effort—executed with the precision, coordination, and innovation that define Vanderbilt’s structural heart program.

Proud of the team, and excited for what’s ahead as we continue to push the field forward.

[Kashish Goel @kashishgoelmd]

@aelsab @MayoClinicCV @DrArgyle @kalazizimd @benhibbertMDPhD Looking forward to this discussion

[Kashish Goel @kashishgoelmd]

@adrianocaixeta Thank you

[Kashish Goel @kashishgoelmd]

Big day in the VUMC cath lab!!

Today, we successfully performed 3 Evoque TTVR procedures — all using intracardiac echo (ICE) only and under MAC sedation.

No TEE. No general anesthesia. Streamlined, efficient, and patient-centered.

This is more than just procedural success — it’s a shift in how we think about TTVR:
· Less invasive
· Faster recovery
· Expanded access for higher-risk patients

A true game changer in structural heart interventions.

Grateful to be pushing the field forward and building on the pioneering work of my friend Pradeep Yadav.

The future of TTVR is here — and it’s simpler, smarter, and safer.